13 companies

ACADIA Pharmaceuticals

Market Cap: US$4.7b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

ACAD

US$28.80

7D

9.3%

1Y

21.0%

CorMedix

Market Cap: US$590.0m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

CRMD

US$7.41

7D

3.1%

1Y

-38.0%

Incyte

Market Cap: US$24.4b

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

New

INCY

US$119.80

7D

-5.7%

1Y

54.3%

Protalix BioTherapeutics

Market Cap: US$191.0m

A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.

PLX

US$2.44

7D

7.5%

1Y

64.9%

TG Therapeutics

Market Cap: US$6.9b

A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

TGTX

US$49.88

7D

-6.7%

1Y

80.1%

CareDx

Market Cap: US$2.4b

Provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.

New

CDNA

US$45.50

7D

28.5%

1Y

247.3%

Eli Lilly

Market Cap: US$994.9b

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.

LLY

US$1,169.86

7D

-3.3%

1Y

56.7%

Rigel Pharmaceuticals

Market Cap: US$716.0m

A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.

RIGL

US$40.48

7D

3.6%

1Y

35.8%

Aurinia Pharmaceuticals

Market Cap: US$1.9b

A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.

AUPH

US$15.19

7D

0.07%

1Y

30.8%

Exelixis

Market Cap: US$14.1b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

EXEL

US$56.70

7D

2.5%

1Y

50.4%

Medpace Holdings

Market Cap: US$16.1b

Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.

MEDP

US$587.75

7D

0.5%

1Y

36.6%

Earth Science Tech

Market Cap: US$26.5m

Together with its subsidies, focuses on health and wellness industry.

ETST

US$0.093

7D

-15.5%

1Y

-46.9%

CapForce

Market Cap: US$84.2m

A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally.

CFOR

US$5.00

7D

-72.2%

1Y

n/a